There is mounting evidence that seemingly diverse psychiatric disorders share genetic etiology, but the biological substrates mediating this overlap are not well characterized. Here we leverage the unique Integrative Psychiatric Research Consortium (iPSYCH) study, a nationally representative cohort ascertained through clinical psychiatric diagnoses indicated in Danish national health registers. We confirm previous reports of individual and cross-disorder single-nucleotide polymorphism heritability for major psychiatric disorders and perform a cross-disorder genome-wide association study. We identify four novel genome-wide significant loci encompassing variants predicted to regulate genes expressed in radial glia and interneurons in the developing neocortex during mid-gestation. This epoch is supported by partitioning cross-disorder single-nucleotide polymorphism heritability, which is enriched at regulatory chromatin active during fetal neurodevelopment. These findings suggest that dysregulation of genes that direct neurodevelopment by common genetic variants may result in general liability for many later psychiatric outcomes.
S
ince the first attempts to establish a consistent nosology in psychiatry 1 there has been an appreciation for the difficulties in delineating patient populations [2] [3] [4] . Without objectively discriminative biomarkers, diagnoses are made through the integration of subjective presentations, including patient experience and behavioral observations [2] [3] [4] . When research diagnostic systems are used in clinically ascertained case-control studies, diagnoses may be designated hierarchically, incorporate perceived severity, censor milder episodes and/or select for archetypical presentations; a process that may obscure complicating co-morbid or pre-morbid episodes 4, 5 . In reality, psychiatric patients may present more heterogeneously, sharing features and blurring boundaries among disorders and between disorders and typical behavior 2, 4, 6 . To some extent this blurring is thought to extend to etiological features, with certain environmental risks predisposing to diverse outcomes 2, 7, 8 , non-specific efficacy of drug treatments implying shared neurochemical pathologies 9 and reports of extensive overlap in genetic risk factors 3, 4 . The large genetic component to susceptibility for psychiatric outcomes is established from consistently moderate to high heritability estimates 10 and this contribution appears shared broadly among disorders. Initial observations of familial co-aggregation and genetic correlations for bipolar disorder (BIP) and schizophrenia (SCZ) 11 have been extended to include other mood disorders, autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) 5, 12, 13 . Recent single-nucleotide polymorphism (SNP)-based investigations of shared polygenetic risk provide further support in patient populations with similar symptom profiles, such as SCZ and BIP 14, 15 or major depressive disorders (MDD) [14] [15] [16] but are also extending this overlap to disorders with more dissimilar clinical profiles such as SCZ and ADHD 15, 17, 18 , anorexia (ANO) 15 or ASD 14, 19 . An emerging hypothesis is that at least a portion of genetic risk for psychiatric disorders is shared or perhaps non-specific with respect to outcomes.
Plausible substrates for such non-specific susceptibility are emerging from molecular genetic studies. The pleiotropic effects of large-effect copy number variants 5, 20 (CNVs) such as 16p11.2 (ref. 21 ), 22q11.2 (ref. 22 ) and NRXN1 (ref. 23 ) suggest insults to neurodevelopment and synaptic function may underlie some of the shared risk. The few studies of common variants directly investigating shared etiology 5 have implicated genes involved in calcium channel neurobiology. A recent integrative transcriptional study surmounted the challenges posed by the reliance on clinical phenotypes and the absence of biomarkers by using post-mortem gene expression profiles across multiple disorders to identify gene sets related to neuronal and astrocytic functions as shared molecular intermediaries 24 . Although plausible hypotheses are emerging, comparatively little has been done to characterize common variants that may have non-specific effects, especially in more representative patient populations.
Here we leverage the unique iPSYCH case-cohort study 25 . iPSYCH is composed of one of the largest single population samples of genotyped psychiatric patients in the world and a representative, random sample from the same national birth cohort. iPSYCH has the unique advantage of ascertaining essentially all major psychiatric patients from a single population and diagnostic schema, uniformly ascertained according to care provided under the same public healthcare system. By comparison, the majority of psychiatric disorder cohorts are ascertained from clinics which may enrich for prevalent (under treatment at the time of ascertainment) cases diagnosed by different schemas and in different populations, confounding, obscuring or otherwise diminishing cross-disorder inferences.
We performed a genetic dissection of this naturalistic and essentially complete patient population ascertained passively from a nation-wide Danish birth cohort , n = 1,472,762) for ADHD, affective disorder (AFF), ANO, ASD, BIP or SCZ (Supplementary Tables 1 and 2 ; Supplementary Fig. 1 ). We perform a diagnosis agnostic cross-disorder genome-wide association study (XDX GWAS) comparing common variant allele frequencies between the entire patient (n = 46,008) and population control cohorts (n = 19,526). We explore the consistency of our findings in published reports and perform an independent replication study in a small, diverse sample from the same birth cohort (n = 7,163). Finally, we integrate published neurobiological data to suppose that the effects of common genetic variants with non-specific associations to psychiatric outcomes are mediated through dysregulation of early neurodevelopmental processes.
Results
The genetic architecture of iPSYCH diagnostic indications. We first asked if the genetic architecture for psychiatric diagnoses in the independent, population-based iPSCYH cohort was consistent with previous reports. The SNP heritability and genetic correlations in iPSYCH are depicted in Fig. 1 Table 3) . We compare our estimates to those from external studies for the same disorders (Fig. 1b and Supplementary  Table 4) , including linkage disequilibrium score regression (LDSC) estimates in seven external GWAS (eGWAS) (Methods): attention-deficit hyperactivity disorder (eADHD), autism spectrum disorder (eASD), major depressive disorder (eAFF), eating disorders (eANO), bipolar disorder (eBIP), schizophrenia (eSCZ) and a cross-disorder (eXDX) GWAS combining portions of eADHD, eAFF, eASD, eBIP and eSCZ. When presented together, the liability scale SNP heritability estimates by genetic restricted maximum likelihood (GREML) and LDSC for the iPSYCH indications are broadly concordant with external studies (Fig. 1b) suggesting an important contribution of common SNPs to underlying liability. LDSC estimates of genetic correlation between iPSYCH indications and eGWAS of the same disorders were generally large (0.44-0.96; Fig. 1c and Supplementary Table 5) , highly significant and consistent with the few previous reports of cross-cohort genetic correlations of the same psychiatric disorder 14, 16 ( Supplementary  Figs. 2 and 3 ). These data suggest that iPSYCH indications capture similar genetic effects to external studies, with expected levels of across cohort genetic heterogeneity. The moderate genetic correlation between XDX and eXDX can likely be explained by differences in the proportion of individual case groups used in the two studies.
GREML point estimates of genetic correlations for all pairs of iPSYCH indications are at least moderate (Fig. 1d , Supplementary  Tables 6 and 7) with the exception of ADHD-ANO (ρ G = 0.01). Standard errors ranged from moderate (0.08) to large (0.39) and were largest for pairs involving the smallest samples (SCZ, 0.21-0.39; BIP, 0.17-0.39). For ADHD-ANO and ANO-BIP standard errors were large enough that we could not reject the null hypothesis, despite moderate point estimates (P > 0.05). Each iPSYCH indication also shows at least moderate genetic correlation with the aggregate of all remaining indications ( Supplementary Fig. 4 ). LDSC estimates of genetic correlation using eGWAS ( Fig. 1d and Supplementary Table 8) trend smaller than for iPSYCH indications of the same disorders, consistent with the additional cross-cohort genetic heterogeneity (Fig. 1c and Supplementary Figs. 2 and 3 ). Despite this, both sets of estimates suggest broad sharing of SNP effects among nearly all pairs of disorders.
A diagnosis agnostic GWAS. Motivated by the appreciable XDX SNP heritability and prevalence of substantial genetic correlations among iPSYCH indications, we performed a diagnosis agnostic GWAS (XDX). We combined all iPSYCH psychiatric patients into a single case cohort (n = 46,008). As GWAS controls (n = 19,526, see Methods) we used the subset of individuals randomly selected from the Danish national biobank (iPSYCH design controls, n = 30,000) with no current diagnoses and passing quality control. We identified four independent loci tagged by genome-wide significant index SNPs (referred to throughout as loci 1-4; P < 5 × 10 −8
; Table 1 and , s.e.m. = 0.01) with an intercept close to unity (1.02; s.e.m. = 0.01) suggests this inflation is likely due to polygenes rather than population stratification or cryptic relatedness.
Although the XDX GWAS is most sensitive to variants with consistent effects across diagnoses, variants strongly associated with a single indication could present as apparent cross-disorder associations. However, rather than showing skewing of the odds ratios for one or two indications, the index SNPs for loci show consistent trends across nearly all indications when association tests were performed comparing the XDX GWAS controls to each single-indication case group (Fig. 2c-f ). This broad pattern holds for suggestive loci (Supplementary Tables 10 and 11 ). The XDX GWAS uncovered multiple loci with non-specific effects on risk across iPSYCH indications that are not driven by a single or small subset of disorders.
Independent statistical support.
We sought independent statistical support for our associations from three sources. First, we queried the top associations from 4,299 GWAS aggregated in the NHGRI-EBI GWAS catalog for connections to our top 50 XDX loci (Methods; Supplementary Table 12 ). NHGRI had independently assigned a category to each GWAS that places psychiatric outcomes within the broader label of 'neurological disorder' . In total, our 50 loci were reported in the top hits of 22 out of 589 neurological disorder GWAS, with nearly all representing psychiatric outcomes more specifically and 21 out of 3,710 GWAS of other traits and diseases (Supplementary Table 12 ), a significant difference (binomial proportion test; P = 3.48 × 10
−13
). Specifically, genome-wide significant loci 2 and 4 and six of the suggestive loci found strong support in domain-relevant studies from the GWAS catalog. Locus 4 was recently reported as genome-wide significant in two meta-GWAS that include the iPSYCH data: one for MDD 16 and one for ADHD 18 . The GWAS catalog contains many studies but very few SNPs from each study, providing an incomplete picture of subtle polygenic trends. Thus, we also mapped our top 50 loci to the best proxy SNP in each of the seven eGWAS described previously (eADHD, eAFF, eANO, eASD, eBIP, eSCZ, eXDX) and, where possible, to the best proxy among the top 10,000 associations from a self-report major depressive disorder GWAS (ref.
26
; eSR-MDD; Table 2, Supplementary Table 13 ). We observe significant external replication (P < 1.56 × 10 −3 correcting for four loci, each tested in eight studies) for locus 2 in the eADHD and eSCZ studies. Locus 4 significantly replicated in the eSR-MDD and eSCZ studies. Even where not individually significant, the association trends are strikingly consistent across all studies for loci 2-4. Importantly, our XDX trend is consistent for each of loci 1-4 and 35 out of 46 suggestive loci, in the eSCZ GWAS; a disorder among the least represented in iPSYCH, emphasizing the plausibility that these loci are non-specific. As a test of this concordance, we used linear regression to ask if, across the top 50 loci, the signed effects (regression statistics; z-scores) for proxy SNPs in the eGWAS are significantly predicted from the XDX effects for the same SNPs. We observed significant concordance (P < 5 × 10 −3 to correct for ten concordance tests) between the XDX effects and the aggregated effects from all Table 1 and full association statistics are presented in Supplementary Tables 10 and 11 . MAF, minor allele frequency; Dx, diagnosis.
seven eGWAS (Fig. 3a) as well as in the eSCZ GWAS alone (Fig. 3b) . Concordance was also significant for the eADHD and eXDX GWAS (Supplementary Figs. 5-11).
As a third form of external validation, we repeated the association tests for each index SNP using linear mixed models in a small, independent replication cohort. We included subjects excluded from the discovery GWAS cohort on the basis of outlying genetic ancestry (replication cohort: n = 7,163 with 4,481 cases; Supplementary Table 1;  results: Table 2, Supplementary Table 14) . Given the reduced sample size we did not expect, nor did we observe, any significant individual replications. We did observe, perhaps surprisingly given the diverse genetic backgrounds, a consistent trend at each of loci and for 31 of the additional 46 suggestive loci. This broad concordance was also significant by the same linear model as above (P = 0.004; Fig. 3c ). Taken together, these analyses provide several forms of independent statistical support for the XDX loci identified here.
Tissue-specific partitioning of non-specific psychiatric diagnosis heritability. Next, we asked if the genetic effects constituting the XDX SNP heritability were stronger among SNPs linked to tissue-specific biological processes. We used LDSC regression for specifically expressed genes 27 (LD-SEG; Methods) to test for an enrichment of SNP heritability in each of 601 SNP sets. The SNP sets were defined by Finucane et al. 27 for proximity to genes preferentially expressed (GTEx and DEPICT sets) or chromatin marks open and active (RoadMap sets) in a variety of human tissues. None of the SNP sets defined by proximity to specifically expressed genes showed evidence for enrichment (false dicovery rate, FDR > 0.05; Supplementary Figs. 12 and 13 and Supplementary Tables 15 and  16 ). Among the SNP sets defined by chromatin marks (Fig. 4a  and Supplementary Table 17) , several related to gene regulation in fetal brain showed significant (P < 6.88 × 10 Table 18 ). Enrichment in the same fetal brain chromatin annotations replicated in the eXDX and eSCZ GWAS, a result described in the LDSC-SEG report 27 ( Fig. 4b and Supplementary Table 19 ). Furthermore, iteratively removing subjects with each indication from the iPSYCH cases and re-estimating enrichment produced consistent results (Fig. 4c and Supplementary Table 20) . Figures 4b,c emphasize the disorder non-specificity of these heritability enrichments. The heritability enrichments for regulatory variants active in fetal brain seen for the XDX GWAS replicate as a class in an independent cross-disorder GWAS (eXDX), in an independent psychiatric GWAS for a disorder (eSCZ) among the least represented in the iPSYCH patient population (Supplementary Fig. 1 ) and are not driven by any single iPSYCH indication. Identifying and characterizing candidate genes. We used FineMap at each of the top 50 loci (GWAS sFDR < 0.05) to identify a set of credible SNPs for each locus (Methods). To identify candidate pathways through a set of plausible candidate genes, each credible SNP was subsequently connected to target genes using chromatin interaction maps for the developing human cortical laminae (Methods). Out of 627 credible SNPs, 400 implicated one or more of 281 candidate genes (160 protein coding; Supplementary Table 21) . As a set, these genes were enriched pathways including axon and dendrite development, receptor tyrosine kinases and histone regulators (Fig. 5a) . Notably, histone regulators and chromatin remodelers have been recently implicated in various psychiatric disorders, including ASD and SCZ 19, 28, 29 . Consistent with the heritability enrichment, the candidate genes were more highly expressed during prenatal stages (P = 1.67 × 10 −10
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; Fig. 5b) , with peak expression during mid-gestation in the human brain (Fig. 5c) . To understand what cells these genes might be functioning in, we leveraged expression profiles of single cells extracted from fetal brain tissue and tested for candidate gene enrichment (Methods). Remarkably, we observe candidates to be enriched for genes preferentially expressed in radial glia, an early form of neural stem cell and interneurons (FDR < 0.05; Fig. 5d ). These results suggest that the cross-diagnosis loci are implicated in corticogenesis and establishment of neural circuits during brain development.
Specific candidate genes implicated by genome-wide significant loci include PDE1A and PPP1R1C for locus 1 (annotated local Manhattan plot, Supplementary Fig. 15 ). PDE1A encodes a Ca 2+ /calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1s) that regulates cAMP and cGMP (ref. 30 ) and can regulate L-type and T-type voltage-gated calcium channels 31 . PPP1R1C encodes an inhibiting regulatory subunit of protein phosphatase 1 (PP1), an enzyme involved in synaptic transmission and plasticity as part of the post-synaptic density 32 and has been shown to regulate neurite growth in cultured neurons 33 . Locus 2 is indexed by an uncommon SNP (MAF = 0.018) and covers a broad, genedense region implicating 53 diverse genes ( Supplementary Fig. 16 ). Among these, DAG1, QRICH1, RNF123 and SMARCC1 harbor de novo risk variants for ASD and CELSR3 for SCZ 34, 35 . IP6K2 is implicated by a well-described gene-enhancer connection (GeneHancer: GH03J048738) 36 and previous studies of SCZ 37 and ADHD
38
. Locus 3 implicates IGSF11 (Supplementary Fig. 17 ), a gene encoding a neuronal adhesion molecule that binds to and stabilizes AMPA receptors regulating synapse development and plasticity 39 . Locus 4 overlaps considerably with the body of SORC3 (Supplementary Fig. 18 ), which encodes a post-synaptic sorting and signaling receptor involved in aspects of neuronal functioning including synaptic plasticity 40 .
Discussion
In this study, we leveraged the uniquely designed iPSYCH study to provide an unprecedented perspective on the overlap in genetic etiology underlying major psychiatric disorders. The iPSYCH cohort , Bonferroni correction for 601 LDSC-SEG enrichment tests) and/or suggestive (FDR < 0.05) enrichment for heritability in SNP sets related to gene regulation in fetal brain tissue. Exact P values and effect sizes are presented in Supplementary Table 17 . b, − log 10 one-sided LDSC-SEG enrichment test P values for the same fetal brain SNP sets in the eSCZ (n = 34,241 cases, 45,604 controls) and eXDX (n = 33,332 cases, 27,888 controls) GWAS replicate enrichments (P < 0.002, Bonferroni correction for 24 replication enrichment tests). Exact P values and effect sizes are presented in Supplementary Table 19 . c, The magnitude of LDSC-SEG enrichment effect estimates for fetal brain tissues in the XDX GWAS (orange) are not qualitatively different when excluding single case groups (non-orange). Gray shading denotes bunches of estimate replicates. Bars denote 95% confidence intervals for enrichment effect estimate. Exact effect sizes and sample sizes are presented in Supplementary Table 20 . Axis numbers (a,b,c) denote SNPs sets defined by narrow peaks of 1, DNase, DNase I hypersensitivity; 2, H3K27ac, histone H3, lysine 27 acetylation; 3, H3K36me3, histone H3, lysine 36 trimethylation; 4, H3K4me, histone H3, lysine 4 methylation; 5, H3K4me3, histone H3, lysine 4 trimethylation; 6, H3K9ac, histone H3, lysine 9 acetylation. AG, adult angular gyrus; AC, adult anterior caudate; CG, adult cingulate gyrus; dlPFC, adult dorsolateral prefrontal cortex; Hipp, adult hippocampus; ITL, adult inferior temporal lobe; SN, adult substantia nigra; cCortex, cortex-derived cultured neurospheres; cGE, ganglion eminencederived cultured neurospheres; GM, geminal matrix; fFetal, female fetal brain; mFetal, male fetal brain.
has the advantage of coming from a nationally representative study interrogating an essentially complete population of patients against a representative sample of diagnosis-free individuals from the same Danish birth cohort. Previous results are based on cohorts identified independently at tertiary research centers by different research groups, often in different countries, factors which could reduce true XDX overlap or shared heritability. Here, patients are ascertained against a uniform background, including genetic background, diagnostic schema, system and other cultural or sociodemographic factors, limiting the potential impact of heterogeneity that may arise when comparing independently ascertained patient cohorts.
These strengths of iPSYCH and the decades of preceding epidemiological research on mental disorders in Danish health registers make iPSYCH uniquely suited for providing robust estimates of genetic parameters. There is less uncertainty in the underlying population that our sample represents and in key parameters, such as the assumed lifetime risk for a particular diagnosis definition in the population, that define the liability scale heritability. Further, the case-cohort, register-based sampling ensures that we capture all individuals diagnosed at the time of ascertainment, while clinical ascertainment may select a subset of patients that are not a representative sample of the population of diagnosed individuals in terms of phenotypic presentation 41 or genetic architecture 42 . The effects of clinical ascertainment may be exaggerated in cohorts collected for GWAS, which may enrich for treatment resistance, archetypical presentation, or features of severity in cases and exceptional mental health in controls, as a means to boost power for single locus discovery. This kind of extreme sampling can create substantial upward bias in liability scale heritability, when not accounted for 43 . The broad trend towards larger genetic correlations estimated within the iPSYCH cohort when compared to those estimated across external studies may be expected given a component of genetic risk for psychiatric disorders that is cohort, study or population specific. The presence of within-population genetic effects is consistent with the trend for genetic correlations of the same disorder between iPSYCH and the corresponding external study to be less than 1. Importantly, we observe the magnitude of these correlations to be similar to the few previous reports 14, 16 , suggesting population-or cohort-specific genetic effects are not a unique feature or flaw of the register-based ascertainment in iPSYCH.
Trends towards lower heritability and higher genetic correlations have also been ascribed to increased rates of misdiagnosis 44 . We emphasize that, although each individual patient was not reassessed when they were enrolled in iPSYCH, the registered diagnoses reflect clinical diagnoses made by trained, certified psychiatrists; small validation studies have shown them to be highly reliable (for examples, see refs. 45, 46 ). Further, it has been suggested 44, 47 that implausibly large numbers of misdiagnosed cases are needed to explain large trends. Schork et al. 47 have undertaken a series of sensitivity analyses to provide broader context for trending differences in the genetic parameters we present here. They consider various differences in aspects of ascertainment between iPSYCH and these external studies including the accuracy of assumed lifetime risk, the age of control subjects, control subjects selected for exceptional mental health, cases selected for genetic severity and levels of misdiagnosis. Their analyses suggest that, for heritability, it is difficult to rule out sampling variability but suggest one plausible contributor to difference trends may be an overestimation due to extreme sampling 43 in external studies. Genetic correlations are more robust to sample ascertainment and we see the most likely contributor to be crosscohort genetic heterogeneity (for example, Fig. 1c) , although more work is needed to fully understand factors that generate variation in genetic correlation estimates from real data.
In general, the broad concordance of the estimated genetic parameters suggests the totality of ascertainment-related factors may be relatively modest, although assessing the true extent of between-population heterogeneity in the genetic architecture of psychiatric will require additional large population-representative cohorts and considerations for ascertainment. With the continued emergence of large population-based ascertainments, such as iPSYCH, 23andMe 26 , the UKBiobank 48 and large insurance record cohorts 49 , we feel this point is critically important for interpreting any differences that may emerge.
It is interesting that our functional interpretations of shared genetic risk factors, both in terms of polygenic trends and with respect to our top associations, converge on fetal neurodevelopmental processes. This epoch has been implicated by previous studies of large effect CNVs and rare or de novo variants but also by environmental exposures (for example, ref.
50
). Such convergence could suggest a critical developmental window during which part of the susceptibility to later psychiatric outcomes is defined. The overlap in timing for the action of genetic and environmental susceptibility factors may also help to carve out a hypothesis space for targeted investigations of gene-environment interactions.
While germline variants are present since the first moments of embryonic development, the chromatin they reside in and genes they may affect undergo a continual evolution of active and inactive states across developmental and life stages. We note that our top associations are potential regulators of genes with familiar functions 14, 29 , (post)synaptic and calcium channel biology. We also demonstrated that, in our study, these variants and their associated genes are most coherently involved in aspects of fetal neurodevelopment. If susceptibility emerges from disruptions to this familiar synapse and calcium channel biology but specifically during neuronal proliferation, migration and establishment of circuits, this could have implications for the development of interventions. To make good on the promise that GWAS can identify plausible pharmacological targets, it will become critical to consider the developmental stages during which variants induce susceptibility. It may be the case that the pathology induced by an associated germline variant occurs in one developmental stage but actionable pharmacological targets represent different downstream molecular pathologies 24 . Explicitly considering the developmental course of pathological susceptibility implied by associated germline variants is a critical next step in the translational promise of GWAS results and emphasizes the importance of partitioning risk with development in mind.
While our study has a number of strengths, it also has a few important limitations. First, we have tried to be comprehensive in our bioinformatics integration of available data resources but experimental work is needed to unequivocally confirm the functional hypotheses that arise from these genetic associations and subsequent candidate gene prioritization. Second, the relative youth of our cohort limits our ability to make strong claims about the effects in adult onset disorders. While we emphasize the evidence for replication in an external study of schizophrenia, future work should further investigate these findings across a broader spectrum of disorders. Third, although our sample is large for a single psychiatric cohort, it is still comparatively modest by GWAS meta-study standards, especially in other common, non-central nervous system disorders. As such, we cannot claim that our results suggest the only mechanisms through which common SNPs may create risk for multiple psychiatric disorders but only that our findings represent a minimal set of features that set the stage for well-informed mechanistic studies. Further, it is also likely that other susceptibility factors are more specific, contributing to the unique presentations of each disorder. Future work could take direct aim at these factors and their interactions with more general susceptibility factors, as we continue to update, partition and functionally characterize our conceptualizations of the genetic architecture underlying major psychiatric disorders.
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Methods
The iPSYCH study cohort and data. The iPSYCH cohort is described in detail elsewhere 25 . Briefly, iPSYCH samples from essentially the entire population of Denmark born between 1981 and 2005 (n = 1,472,762). In total, 87,764 individuals were selected. A total of 30,000 design controls were selected randomly from this birth cohort, without regard for psychiatric disorders, to create a representative population sample. The remaining 57,764 design cases were ascertained for indications of clinical diagnoses recorded in the Danish Civil 51 ). Care administered by primary care or private practice physicians is not recorded into national registers. Diagnoses before 1994 were associated with codes from the ICD 8th revision 58 and converted to equivalent ICD 10th revision 57 (ICD10) codes to match the majority of indications 56 . We define the following seven cases groups as having at least one indication with the corresponding ICD10 (or equivalent ICD8) codes: cross-diagnosis (XDX: F00-99), attention-deficit/ hyperactivity disorder (ADHD: F90.0), affective disorders (AFF: F32-F39), anorexia (ANO: F50.0, F50.1), autism spectrum disorders (ASD: F84.0, F84.1, F84.5, F84.8, F84.9), bipolar disorder (BIP: F30-31), and schizophrenia (SCZ: F20). As an additional case group, we consider those patients with other psychiatric indications, exclusively (OTH: F00-F99 not listed previously, only). Case status can reflect the presence of a single or multiple indications and were not censored or integrated hierarchically. The counts, prevalence and co-occurrence of indications are shown in Supplementary Tables 1 and 2 and co-occurrence is depicted in Supplementary Fig. 1 .
Initial genotyping was performed at the Broad Institute with amplified DNA extracted from dried blood spots and assayed on the Inifinium PsychChip v1.0 array 25 . In total, 78,050 subjects were successfully genotyped across 25 waves at approximately 550,000 SNPs. A subset of good-quality common SNPs (n = 246,369) were phased into haplotypes in a single batch using SHAPEIT3 59 and imputed in ten batches using Impute2 (ref. 60 ) with reference haplotypes from the 1,000 genomes project phase 3 (ref. 61 ). Imputed additive genotype dosages and best-guess genotypes were checked for imputation quality (INFO > 0.2), deviations from Hardy-Weinberg equilibrium (HWE; P < 1 × 10
), association with genotyping wave (P < 5 × 10 ) as well as censored on MAF > 0.01). In total, 8,018,013 imputed dosages and best-guess genotypes were used for analysis.
Three sets of cohorts of unrelated subjects with homogenous genetic ancestry were created by sub-setting the design cohorts, one for our primary GWAS analyses (GWAS cohorts) and two for heritability by either LDSC regression analysis (LDSC cohorts) or by GREML SNP heritability analysis (GCTA cohorts). Genetic ancestry for all cohorts was characterized using principal components analysis using smartPCA implemented in the Eigensoft package v6.0.1 (refs. 62, 63 ). We performed two iterations of censoring, removing subjects outlying from joint distribution of the first ten principle components defined in the subset of iPSYCH with four grandparents recorded in the Danish civil register as born in Denmark (n = 6,474 outliers removed; Supplementary Fig. 24 ), re-computing principle components on the remaining subjects and censoring again according to the same criteria (n = 689 outliers removed; Supplementary Fig. 25 ). Censored individuals were aggregated into a fourth ancestry diverse cohort (Replication cohort). For the GWAS and LDSC cohorts kinship was estimated using KING v1.9 (ref. 64 ) and individuals were censored to ensure no pair had closer than third degree kinship (n = 4,988 removed). For the GCTA cohorts, kinship was more strictly filtered such that no pair had GCTA-based estimate greater than 0.034, the absolute value of the minimum estimated kinship (n = 22,223 removed). When possible cases were retained and the control relative was censored. All subject genotypes were flagged for abnormal sample heterozygosity, high levels of missing genotypes (> 1%), sex concordance and inconsistencies among duplicate samples and those failing one or more tests were excluded (n = 364). In total, 65,534 subjects were retained in the GWAS and LDSC cohorts, 43,311 in the GCTA cohorts and 7,163 in the Replication cohort. A more detailed quality control protocol is available in our consortium white paper posted with our GWAS summary statistics (https://ipsych. au.dk/downloads/).
For the GWAS cohort, control subjects were defined as the subset of the design controls with no indications of any mental disorders. This cohort was used for XDX LDSC heritability, XDX-eXDX genetic correlation, XDX GWAS, singleindication odds ratios in Fig. 2c-f , and LDSC-SEG analysis. The same control definition was applied to the Replication cohort for internal replication tests. For the LDSC and GCTA cohorts, the definition of control subjects was different for each indication. Control subjects were the subset of the design controls without that indication, only, and are expected to have other indications at the population prevalence, consistent with a representative sample of the population without the considered diagnosis. These cohorts were used for single-indication GCTA and LDSC heritability and genetic correlation analyses. Unless explicitly noted, cases cohorts include all individuals with a specified indication, including those with co-morbid diagnoses.
Statistical analyses. All statistical tests were two-sided, unless specifically noted and assumptions (for example, data distribution, homoscedasticity and so on) were not formally tested. Randomization and blinding procedures do not apply to our study design.
SNP heritability and genetic correlations. SNP heritability and genetic correlations were estimated in the GCTA cohorts with the GREML approach available in GCTA v1.25.2 (refs. [65] [66] [67] ). Age, gender and ten principal components were included as fixed-effects covariates. Estimates were converted to the liability scale 67 according to estimates of lifetime risk take from Pedersen et al. 56 (Supplementary Table 2 ). Estimation of genetic correlation between indications was performed using bivariate GREML 66, 68 . For each pair of phenotypes, subjects with both indications were excluded and controls were randomly and evenly split, creating two independent case-control groups. Splitting and estimation were repeated five times for each pair and the median values were retained.
Published GCTA SNP heritability estimates for ADHD, AFF, ASD, BIP and SCZ were taken from Lee et al. 14 . GREML estimates of SNP for ANO and XDX were unavailable. GWAS statistics for eXDX 55 , eADHD 69 , eAFF 70 , eANO 71 , eASD 72 and eSCZ 73 were downloaded from the Psychiatric Genomics Consortium (PGC) repository (http://www.med.unc.edu/pgc/results-and-downloads). Statistics for eBIP (ref. 75 ) were downloaded from the NHGRI-EBI GWAS catalog 75 . Linkage disequilibrium score regression (LDSC v1.0.0) 76 was used to estimate SNP heritability for these published studies and for each single iPSYCH indication. Reference LD scores and protocol were provided by the authors (https://github. com/bulik/ldsc/wiki). Genetic correlations between iPSYCH indications and published GWAS were estimated with LDSC 15 using the authors' protocols. For LDSC regression heritability and genetic correlation, single-indication iPSYCH GWAS were performed in the LDSC cohort according to the analysis approach described below. To facilitate comparisons a typical population prevalence was used for each liability scale transformation (XDX = 0.35, ADHD = 0.05, AFF = 0.15, ANO = 0.01, ASD = 0.01, BIP = 0.01, SCZ = 0.01) 14, 71 , including re-scaling the iPSYCH GREML estimates.
Association testing. GWAS were performed using imputed additive genotype dosages and logistic regression implemented in PLINK v1.90 (ref. 77 ). The XDX GWAS included all subjects in the GWAS cohort (46,008 cases, 19,526 controls). Inflation was assed via genomic inflation factor (λ GC ) 78 and LDSC 76 . Age, gender and ten principal components were included as fixed effects covariates. Stratified false discovery rates 79 (sFDR) were estimated according to Story's q value 80 and computed independently for common (MAF ≥ 0.05) and uncommon SNPs (0.01 < MAF < 0.05). The suggestive SNP threshold of sFDR q value < 0.05 corresponds to a P value less than 1.02 × 10 −5 for common SNPs and less than 4.71 × 10 −7 for uncommon SNPs. Single-indication odds ratios in Fig. 2c-f and XDX GWAS excluding each single indication used in Fig. 4 were performed to provide context for the XDX results in the GWAS cohort. For the internal replication cohort (7,163 individuals, 4,481 cases), association tests used best-guess genotypes and linear mixed models implemented in GCTA 66 accounting for relatedness and heterogeneity in genetic background with genome-wide estimates of empirical kinship. Gender and age were included as fixed-effects covariates.
Fine mapping. Region-based loci associated with independent index SNPs were defined and refined iteratively. The most significant SNP was selected and PLINK v1.90 77 (https://www.cog-genomics.org/plink/1.9/) was used to estimate pairwise r 2 LD between the index SNP and all SNPs within five megabases. All SNPs with r 2 LD > 0.1 with the index SNP were considered index-associated SNPs. Locus bounds were determined by the physical positions of the furthest index-associated SNP upstream and downstream. The process was repeated until all suggestive SNPs were labeled as index or index-associated SNPs. Loci with overlapping indexassociated SNP sets were merged. Conditional analysis was performed within each locus, including the imputed dosage for the most significant SNP as a covariate and re-computing within locus association statistics. Secondary suggestive SNPs were retained as independent index SNPs and the process was repeated until no SNPs within the locus showed suggestive association. Credible SNPs were defined for each locus using FineMap v1. For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
In accordance with the consent structure of iPSYCH and Danish law, individual level genotype and phenotype data are not able to be shared publicly. Cross-disorder (XDX) GWAS summary statistics are available for download (https://ipsych.au.dk/downloads/). Summary statistics from secondary GWAS of single disorders are
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available upon request from the corresponding author.
Field-specific reporting Behavioural & social sciences study design
All studies must disclose on these points even when the disclosure is negative.
Study description
A genome-wide associate study of lifetime psychiatric diagnoses as of 2012 in a 1981-2005 birth cohort .
Research sample
We used data from the iPSYCH case-cohort study: A random, representative sample of the Danish neonatal biobank for individuals born between 1981 and 2005, with a known mother, alive on their first birthday, who have not opted out of the Danish national register based research program and the complete population of individuals from the Danish population birth cohort meeting the same inclusion criteria and with a major psychiatric diagnosis in the national registers as of 2012. The case sample was chosen to be complete and the random population sample to be representative and of comparable size to the largest individual case cohort. Further details can be found in PMID: 28924187.
Sampling strategy
Data was ascertained according to a case-cohort design where the size of the cohort (random sample) was chosen to represent 2% of the broader population it was sampled from ( population of Denmark born between 1981 and 2005). Cases were all cases in the population at the time of ascertainment. These samples are state-of-the-field for single cohort GWAS studies, representing the largest of its kind, and consistent with previous reports adequately powered for discovery.
Data collection
We used data from the iPSYCH case-cohort study: DNA was extracted from dried neonatal blood spots and amplified before genotyping on the Infinium PsychChip v1.0. Blood was collected between 4-7 days after birth and stored at -20 C until the time of ascertainment. Psychiatric diagnoses were aggregated from national registers. Demographic and social variables were aggregated from national civil registers. Further details can be found in PMID: 28924187.
Timing
All data was initially collected in 2012 and psychiatric diagnoses were later updated, complete through 2014.
Data exclusions
Among the 78,050 samples with genotype data available in the iPSYCH case-cohort study, 5,353 were excluded according to genotype and imputation quality control procedures described in great detail in Supplementary Note 2. These data exclusion criteria were determined before the study was designed or conducted.
Non-participation
All subjects in the iPSYCH case-cohort data resource were initially included. This sample was drawn only from those meeting consent requirements.
Randomization
When control samples were split into random sub-cohorts for analysis the sample() function in R was used to select subsamples of subject unique IDs.
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